Stock PHIO PHIO PHARMACEUTICALS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Phio Pharmaceuticals Corp.

Equities

PHIO

US71880W4024

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.682 USD -3.40% Intraday chart for Phio Pharmaceuticals Corp. +6.58% -10.26%
Apr. 22 Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762 CI
Apr. 16 Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization 1 6.296 15.55 13.53 5.084 1.857 3.242
Enterprise Value (EV) 1 6.296 15.55 13.53 5.084 1.857 3.242
P/E ratio -0.49 x -1.4 x -0.96 x -0.44 x -0.15 x -0.2 x
Yield - - - - - -
Capitalization / Revenue 300 x - - - - -
EV / Revenue 300 x - - - - -
EV / EBITDA - - - - - -
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) 55.8 482 1,128 1,139 2,443 4,592
Reference price 2 112.9 32.28 12.00 4.464 0.7600 0.7060
Announcement Date 3/26/20 3/25/21 3/22/22 3/22/23 4/1/24 -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales 1 0.021 - - - - -
EBITDA - - - - - -
EBIT 1 -8.987 -8.793 -13.51 -11.46 -10.82 -13.4
Operating Margin -42,795.24% - - - - -
Earnings before Tax (EBT) 1 -8.908 -8.794 -13.29 -11.48 -10.83 -13.4
Net income 1 -8.908 -8.794 -13.29 -11.48 -10.83 -13.4
Net margin -42,419.05% - - - - -
EPS 2 -232.0 -23.04 -12.48 -10.10 -5.200 -3.560
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/26/20 3/25/21 3/22/22 3/22/23 4/1/24 -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q2 2023 Q3 2023 Q4
Net sales 1 - - - - - - - - -
EBITDA - - - - - - - - -
EBIT 1 -3.739 -3.45 -2.64 -2.521 -3.571 -2.73 - -2.776 -1.899
Operating Margin - - - - - - - - -
Earnings before Tax (EBT) 1 -3.742 -3.451 -2.642 -2.531 -3.576 -2.731 - -2.78 -1.895
Net income 1 -3.742 -3.451 -2.642 -2.531 -3.576 -2.731 -2.549 -2.78 -1.895
Net margin - - - - - - - - -
EPS 2 -3.360 -3.120 -2.280 -2.280 -3.120 -2.420 -1.470 -1.140 -0.1700
Dividend per Share - - - - - - - - -
Announcement Date 11/10/21 3/22/22 5/12/22 8/11/22 11/10/22 3/22/23 8/10/23 11/9/23 4/1/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 3/26/20 3/25/21 3/22/22 3/22/23 4/1/24 -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.706 USD
Average target price
4 USD
Spread / Average Target
+466.57%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PHIO PHARMACEUTICALS CORP. Stock Phio Pharmaceuticals Corp.
-10.26% 3.24M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.59B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 40.65B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 40.57B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 24.81B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.7B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11.1B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PHIO Stock
  4. Financials Phio Pharmaceuticals Corp.